Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis

Autor(es)

Alcantara, Laura M. ^[1] ; Ferreira, Thalita C. S. ^[1] ; Gadelha, Fernanda R. ^[1] ; Miguel, Danilo C. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Campinas UNICAMP, Biol Inst, Campinas, SP - Brazil

• Tipo de documento: Artigo de Revisão
• Fonte: INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE; v. 8, n. 3, p. 430-439, DEC 2018.
• Citações Web of Science: 14

Resumo

Tritryps diseases are devastating parasitic neglected infections caused by Leishmania spp., Trypanosoma cruzi and Trypanosoma brucei subspecies. Together, these parasites affect more than 30 million people worldwide and cause high mortality and morbidity. Leishmaniasis comprises a complex group of diseases with clinical manifestation ranging from cutaneous lesions to systemic visceral damage. Antimonials, the first-choice drugs used to treat leishmaniasis, lead to high toxicity and carry significant contraindications limiting its use. Drug-resistant parasite strains are also a matter for increasing concern, especially in areas with very limited resources. The current scenario calls for novel and/or improvement of existing therapeutics as key research priorities in the field. Although several studies have shown advances in drug discovery towards leishmaniasis in recent years, key knowledge gaps in drug discovery pipelines still need to be addressed. In this review we discuss not only scientific and non-scientific bottlenecks in drug development, but also the central role of public-private partnerships for a successful campaign for novel treatment options against this devastating disease. (AU)

• Processo FAPESP: 15/24595-9 - Correlação entre os parâmetros bioquímicos de isolados de Trypanosoma cruzi de pacientes portadores de diferentes formas clínicas da doença de Chagas e a patogênese da doença
• Beneficiário: Fernanda Ramos Gadelha
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/21129-4 - O papel das proteínas ligantes de ácidos graxos na infecção de macrófagos por Leishmania: um alvo potencial para novas drogas contra leishmaniose
• Beneficiário: Danilo Ciccone Miguel
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores
• Processo FAPESP: 15/10436-6 - Descoberta de novos compostos para tratamento da Leishmaniose cutânea e mucocutânea a partir de high content screening
• Beneficiário: Thalita Camelo da Silva Ferreira
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto